What is the approximate market price of bimetinib as a targeted drug? Will there be a price difference?

Binimetinib, as a MEK inhibitor, is mainly used to treat advanced or metastatic melanoma. Especially when combined with a BRAF inhibitor, it can significantly improve the efficacy. Although the drug has been approved in many countries and regions, it has not yet been approved by the Food and Drug Administration for marketing in China, and patients need to purchase the drug through overseas channels. The price of bimetinib varies greatly due to the difference between the original drug and generic drugs. Patients need to consider their economic status and treatment needs when choosing.

The original version of bimetinib is mainly sold through Hong Kong pharmaceutical channels. Taking the Hong Kong version as an example, the price of bimetinib with a specification of 15 mg × 84 tablets is about more than 10,000 yuan per box. This price is relatively high in the international market, and it usually needs to be purchased through cross-border drug purchase or other channels. Due to the higher research and development costs of original drugs, as well as the tariffs and freight charges that may be involved in the import process, their prices remain at a high level.

Compared with the original drugs, there are also some cheaper generic versions on the overseas market. For example, the generic version of bimetinib produced by LuShius Pharmaceuticals in Laos sells for about 6,000 yuan per box with the same specifications. Although generic drugs have a greater price advantage, their ingredients and efficacy are almost the same as those of the original drugs, and they comply with international drug standards, making them the first choice for many patients. For patients with limited financial conditions, generic drugs are a viable option, especially in the case of long-term treatment, which can effectively reduce the financial burden.
Overall, although there are significant differences in the market price of bimetinib, patients should make a choice based on their own condition and economic status, whether they choose the original drug or a generic drug. Since bimetinib has not yet been launched in China, patients need to purchase it through formal international drug channels and use it under the guidance of a doctor to ensure the safety and effectiveness of the drug.
Reference: https://go.drugbank.com/drugs/DB11967